Search

Humbled and thrilled to receive our NIH/NCI R01 grant!

It is a 5-year $3.07M grant for a prospective clinical trial with our E-Slice assay to predict Triple Negative Breast Cancer patient treatment responses to standard of care.

Huge thanks to collaborators Dr. Kyuson Yun, Houston Methodist/Weill-Cornell Med, and Dr. Naoto Ueno at MD Anderson Cancer Center. #E-Slice #NIH #NCI # R01 #TNBC #MDACC #HMRI #Breastcancer #Immunotherapy #Cancertreatment #Precisiononcology

We are excited and grateful to announce being awarded "Most Promising Company" following the pitch competition at the 2022 Texas Life Science Forum! #lifescience#precisionmedicine#oncology#biotech


030922 Empiri TLSF press release
.pdf
Download PDF • 28.32MB


EMPIRI has been selected to present at the Texas Life Science Forum on February 24, 2022, at the Jones Graduate School of Business, McNair Hall, Rice University, Houston, Texas. Company Showcase and Investor Office Hours will be held the day before the Forum. #lifescience#business#pitchcompetition#biotechnology#startup#medtechinnovator#meddevice#cancertreatment#cancercare#cancerdiagnostics#cancerpatients